The UK CARDIO‑IMID Partnership is delighted to announce successful activation of the first two clinical sites participating in the UK CARDIO‑IMID Registry Study. This marks an important milestone in our national effort to better understand and improve outcomes for patients living with immune‑mediated inflammatory diseases (IMIDs) and associated cardiovascular complications.
The newly activated sites— The Royal Infirmary of Edinburgh (NHS Lothian) and Countess of Chester Hospital NHS Foundation Trust —will now begin recruiting participants to the Registry. Each site will contribute valuable real‑world data to help build a comprehensive, UK‑wide picture of cardiovascular risk, clinical pathways, and long‑term outcomes across diverse IMID populations.
The Registry Study is a core component of the Partnership’s mission to accelerate research, strengthen clinical collaboration, and inform evidence‑based improvements in patient care. With these first activations complete, several additional sites are expected to come online in the coming months.
We would like to thank the investigators, research nurses, and delivery teams at both sites for their hard work in progressing site setup and dedication to advancing cardio‑rheumatology research. Activation of further centres will continue throughout 2026 as we work toward building a robust national Registry.
For more information about the UK CARDIO‑IMID Partnership or updates on the Registry Study, please visit our Research Team page or contact the study team at [email protected] and [email protected].
